Procept Biorobotics Faces Class Action Lawsuit Over Inventory Claims

The legal action, filed in the United States District Court for the Northern District of California, concerns the period between February 28, 2024, and February 25, 2026. According to the complaint, Procept repeatedly assured the market that handpiece unit sales served as a reliable proxy for clinical demand. Management allegedly attributed revenue volatility to external factors, such as temporary saline shortages, rather than revealing that handpiece sales were consistently outpacing actual procedures by 8% to 16% each quarter since early 2023.

This discrepancy became a focal point for shareholders following a series of disclosures that concluded on February 25, 2026. The company eventually reported that excess field inventory had reached 10,000 units, coinciding with a 30% sequential contraction in unit sales. Following these revelations, Procept shares experienced a decline of approximately 75%, representing a loss of roughly $75 per share from their peak during the class period. The law firm Levi & Korsinsky is representing investors seeking to recover losses linked to these allegedly inflated stock prices.